Johnson & Johnson (JNJ) Q4 2025 Earnings

No. Johnson & Johnson reported Q4 2025 earnings of $2.46 a share on Jan 21, 2026, missing the $2.46 consensus estimate by 0.2%. Revenue was $24.6B against a $24.2B estimate.

Johnson & Johnson closed out 2025 on a high note, reporting Q4 revenue of $24.56 billion — up 9.1% year-over-year and ahead of the $24.13 billion Wall Street had expected — while adjusted EPS of $2.46 matched consensus exactly, representing a 20.6% jump from the prior-year period. The standout driver was the Innovative Medicine segment, where oncology powerhouse DARZALEX surged 26.6% to $3.90 billion and TREMFYA soared 67.6% to $1.59 billion, more than offsetting a steep 47.7% decline in STELARA amid biosimilar pressure. MedTech contributed meaningfully as well, with cardiovascular sales climbing 11.5% to $2.30 billion — a gain that comes as J&J makes inroads in electrophysiology, adding competitive pressure on rivals in the pulsed field ablation space. Full-year sales reached $94.19 billion, and management is guiding for roughly $100.50 billion in 2026 revenue alongside adjusted EPS of $11.53 — projections that reflect confidence in a <a href="https://247wallst.com/investing/2026/01/10/the-glp-1-blockbuster-maker-widens-its-lead-as-the-diversified-healthcare-giant-posts-steady-growth/">diversified growth trajectory</a> anchored by oncology momentum and a planned Orthopaedics separation.